Fowler Joseph F, Nebus Judith, Wallo Warren, Eichenfield Lawrence F
Division of Dermatology, University of Louisville, Louisville, KY, USA.
J Drugs Dermatol. 2012 Jul;11(7):804-7.
Colloidal oatmeal has been used for decades to soothe and ameliorate atopic dermatitis and other pruritic and/or xerotic dermatoses. In-vitro and/or in-vivo studies have confirmed the anti-inflammatory, barrier repair, and moisturizing properties of this compound. A broad set of studies has been conducted in recent years to assess the effects of colloidal oatmeal as adjunct treatment in the management of atopic dermatitis (AD). This paper will review these studies. In these investigations, patients in all age groups (3 months to 60 years) with mild to moderate atopic dermatitis were included and allowed to continue their prescribed topical medications. These studies found that the daily use of moisturizers and/or cleansers containing colloidal oatmeal significantly improved many clinical outcomes of atopic dermatitis from baseline: investigator's assessment (IGA), eczema area and severity index (EASI), itch, dryness, and quality of life indices. Safety results showed that the formulations were well tolerated in babies, children, and adults with AD.
几十年来,胶态燕麦片一直被用于舒缓和改善特应性皮炎以及其他瘙痒性和/或干性皮肤病。体外和/或体内研究证实了这种化合物的抗炎、屏障修复和保湿特性。近年来,已经进行了一系列广泛的研究,以评估胶态燕麦片作为辅助治疗在特应性皮炎(AD)管理中的效果。本文将对这些研究进行综述。在这些调查中,纳入了所有年龄组(3个月至60岁)患有轻度至中度特应性皮炎的患者,并允许他们继续使用规定的外用药物。这些研究发现,每天使用含有胶态燕麦片的保湿剂和/或清洁剂可使特应性皮炎的许多临床结果从基线显著改善:研究者评估(IGA)、湿疹面积和严重程度指数(EASI)、瘙痒、干燥和生活质量指数。安全性结果表明,这些制剂在患有AD的婴儿、儿童和成人中耐受性良好。